According to the new report by Rockville Research titled ?Global Molecular Diagnostics Market - Focus on Infectious Diseases (HPV/Chlamydia/Gonorrhea) & Genetic Testing (HLA) - Industry Outlook 2022?, there has been unprecedented rise in sexually infected diseases such as Chlamydia and Gonorrhea, particularly in the US. CT/NG is most prevalent sexually transmitted diseases (STD) in the US with consistent rise in the number of Chlamydia and Gonorrhea cases. The Government has also recommended regular screening for patients belonging to two of the major segments of the molecular diagnostics market: HPV and CT/NG.
The report ?Global Molecular Diagnostics Market - Focus on Infectious Diseases (HPV/Chlamydia/Gonorrhea) & Genetic Testing (HLA) - Industry Outlook 2022? provides an in-depth analysis of global molecular diagnostics market which is estimated to be valued at US$ 6.7 billion in the year 2016 and projected to reach US$ 11.4 billion by 2022, growing at a CAGR of 9.3% in the period 2016-22. The report focuses on Infectious Diseases (HPV/Chlamydia/Gonorrhea) & Genetic Testing (HLA). The infectious diseases segment dominates the molecular diagnostics market by application with HPV dominating in virology segment and CT/NG in bacteriology segment. It provides details on current and forecasted scenario of each of aforementioned diseases.
Growth of the market is driven by prevalence of reproductive infectious diseases such as Chlamydia and Gonorrhea, surge in various types of oncology diagnostics, ageing population and government?s mandate on regular screening of HPV and CT/NG. However, growth of the industry is incumbent due to ambiguity in relation to reimbursement guidelines and presence of complex regulatory framework. Global Molecular Diagnostics market is dominated by few major companies, of which Roche Holding, Novartis AG, Hologic Inc., and Qiagen NV have been covered in the report.

Molecular diagnostics is used for detecting patient?s susceptibility to a disease by tests for detecting and characterizing pathogenic mutations in DNA and RNA samples. It is the most dynamic segment of the global in vitro diagnostics market, given the advantages of precise genetic information over traditional tests. Molecular diagnostics in healthcare has been disseminating around the world at a robust growth rate due its unique ability to unlock molecular information of patients. The market has burgeoned in span of 25 years. It is further poised to reach new heights by breaching US$ 11 billion mark by 2022 by growing at a CAGR of 9.2% in the forecasted period 2016-22.
In terms of market structure, molecular diagnostics industry is classified into three broad categories - clinical infectious disease, genomics and blood donor screening. The clinical infectious disease segment has two sub-segments: virology and bacteriology tests. The genomics segment is further sub-divided into genetic diseases and disorders, cancer testing, HLA testing, and pharmacogenetic testing. Infectious diseases are the largest segment of molecular diagnostics market.
Growth of the industry is fuelled by prevalence of reproductive infectious diseases such as Chlamydia and Gonorrhea, surge in various types of oncology diagnostics, ageing population and government?s mandate on regular screening of HPV and CT/NG. However, complex regulatory framework and lack of clarity on reimbursement are the major factors restraining the growth of the molecular diagnostics market. Key trends prevailing in the industry includes rise in number of strategic industry alliances and use of Next Generation Sequencing (NGS) in clinical molecular diagnostics.
The report provides information on the current scenario, detailed market outlook of the molecular analysis market segments such as Infectious diseases with focus on Human Papilloma virus (HPV) in virology segment and Chlamydia and Gonorrhoea in bacteriology segment. It further analyzes genomics testing market with focus on Human Leukocyte Antigen (HLA) testing. Lastly, Blood Donor Screening market is analysed in the report. Future forecasts on all prominent application areas of the industry till 2022 is also provided in the report. Furthermore, key industry players have been prudently analysed in the competitive landscape section of the report in order to provide key comparative insights.
Major industry players operating in the market include Roche Holding AG, Novartis AG, Hologic Inc, Abbott Diagnostics, Becton Dickinson and Qiagen NV, among others. Roche Holdings, Novartis AG, Hologic Inc and Qiagen NV are profiled herein based on attributes such as business overview, product segments, financial and business strategies. It also compiles performance comparison of aforementioned companies and other leading companies in the segment based on various parameters in the competitive landscape section. In totality, the report provides detailed market analysis, with relevant forecasted data supported by key market dynamics. This information will be helpful in evaluating opportunities in global molecular diagnostics market.